Chimeric Antigen Receptor Modified T Cells Infusion
Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma
Explore 36 assets in Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma →Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Shandong Qilu Cell Therapy Engineering Technology Co., Ltd
Modality
Cell therapy
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07048353CT.gov CD30 CAR-T in the Treatment of CD30 Positive Lymphoma | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Chimeric Antigen Receptor Modified T Cells Infusion (this asset) | Shandong Qilu Cell Therapy Engineering Technology Co., Ltd | Early P1 | C · 39 |
| Cyclophosphamide | City of Hope Medical Center | P2 | BB |
| Etoposide | Alliance for Clinical Trials in Oncology | P4 | BB |
| Dexasone | Zhengzhou University | P4 | BB |
| (+)-Vincristine | City of Hope Medical Center | P2 | BB |
| Nivestim | City of Hope Medical Center | P2 | BB |
| Adriamycin | City of Hope Medical Center | P2 | BB |
| Prednisone | City of Hope Medical Center | P2 | BB |
| Romidepsin | Walter Hanel | P2 | BB |
+42 more in the Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma cohort
Other indications for Chimeric Antigen Receptor Modified T Cells Infusion
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lymphoma | — | P2 | B · 61 |
| B-Cell Non-Hodgkin Lymphoma | — | P2 | B · 59 |
| Lymphoid Leukemia | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Chimeric Antigen Receptor Modified T Cells Infusion in Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/chimeric-antigen-receptor-modified-t-cells-infusion-mature-t-cell-and-nk-cell-non-hodgkin-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →